Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Non Operating Income (2021 - 2025)

Senti Biosciences has reported Non Operating Income over the past 5 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at $4.2 million for Q4 2025, down 49.5% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 197.51% YoY), and the annual figure for FY2025 was $7.3 million, down 11.01%.
  • Non Operating Income for Q4 2025 was $4.2 million at Senti Biosciences, up from -$1.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for SNTI hit a ceiling of $14.7 million in Q4 2021 and a floor of -$13.7 million in Q3 2024.
  • Median Non Operating Income over the past 5 years was $21000.0 (2021), compared with a mean of $1.2 million.
  • Biggest five-year swings in Non Operating Income: soared 362950.0% in 2023 and later tumbled 288.0% in 2024.
  • Senti Biosciences' Non Operating Income stood at $14.7 million in 2021, then tumbled by 100.03% to -$4000.0 in 2022, then skyrocketed by 350.0% to $10000.0 in 2023, then skyrocketed by 82450.0% to $8.3 million in 2024, then plummeted by 49.5% to $4.2 million in 2025.
  • The last three reported values for Non Operating Income were $4.2 million (Q4 2025), -$1.2 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.